✨ Free AI Report
Formycon AG: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Formycon AG
Research Preview

Formycon AG: Business Overview, Financials & Competitive Analysis

Formycon is a German biopharmaceutical company specializing in the development and commercialization of biosimilar drugs. The company maintains an approved portfolio of ranibizumab, ustekinumab, and aflibercept biosim...

Analyst-debate audio for Formycon AG

AskCyborg analysts argue the bull and bear cases for Formycon AG across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Formycon AG OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
6/ 10Solid

Cyborg Score thesis

Formycon offers exposure to the growing biosimilars market with three approved products and a promising pipeline, though...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Biosimilars
3 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 15, 2026
AI-Verified Research
30+ Page Report

Get the Latest Formycon AG Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Formycon AG Overview

Pro stress-test →

Formycon is a German biopharmaceutical company specializing in the development and commercialization of biosimilar drugs. The company maintains an approved portfolio of ranibizumab, ustekinumab, and aflibercept biosimilars, with a pipeline extending into immuno-oncology and immunology indications.

Strategic Profile

Pro stress-test →

Formycon operates as an independent biosimilars specialist with a scalable development platform covering ophthalmology, immunology, and chronic disease treatment. The company leverages an established infrastructure for biosimilar development from early-stage analysis through clinical testing and regulatory approval preparation.

Competitive Landscape

Pro stress-test →

Formycon competes in the biosimilars market dominated by Sandoz, Amgen, Pfizer, and other established players. The company differentiates through a focused specialist approach and integrated platform, though competitive intensity remains high in approved indications. Smaller peers like Coherus and larger generics players represent both direct and indirect competition.

Industry Context

Formycon AG operates in Biopharmaceutical - Biosimilars.

Key facts

Founded: 2012 · Headquarters: Martinsried, Germany · Revenue: $56.2M · Market cap: $512M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Formycon AG.

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Formycon AG has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Biosimilar portfolioDominant global biosimilars player with broader portfolio→Biosimilar franchiseLarge integrated biotech with biosimilar capabilities→Biosimilar offeringsDiversified pharma with growing biosimilar focus→

Compare Formycon AG with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Formycon AG operates in Biopharmaceutical - Biosimilars. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Biosimilars research →
NEW · MCP server

Ask your AI assistant about Formycon AG

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Formycon AG and its top competitor on Cyborg Score”
“What did Formycon AG do this quarter?”
“Is Formycon AG a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Formycon AG do?+
Formycon is a German biopharmaceutical company specializing in the development and commercialization of biosimilar drugs. The company maintains an approved portfolio of ranibizumab, ustekinumab, and aflibercept biosim...
What is Formycon AG's Cyborg Score?+
Formycon AG has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Formycon AG's main competitors?+
Named competitors include Biosimilar portfolio, Biosimilar franchise, Biosimilar offerings. The full competitive landscape is in the AskCyborg report.
How can I get the full Formycon AG research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Formycon AG research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Formycon AG over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Anthropic9Dubai Electricity and Water Authority (DEWA)9Emaar Development PJSC9Gold Fields Limited9Western Digital Corporation9Advantest Corporation9Fast Retailing Co., Ltd.9JPMorgan Chase & Co.9Siemens AG9Space Exploration Technologies Corp8Arcellx, Inc.8Gentili Mosconi S.p.A.8Neurogene Inc.8Selvaag Bolig ASA8Satellogic Inc.8Klaveness Combination Carriers ASA8Unusual Machines, Inc.8Shoei Co., Ltd.